These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 9516220

  • 1. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.
    Schwartz S, Raskin P, Fonseca V, Graveline JF.
    N Engl J Med; 1998 Mar 26; 338(13):861-6. PubMed ID: 9516220
    [Abstract] [Full Text] [Related]

  • 2. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
    Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL.
    Ann Intern Med; 2001 May 01; 134(9 Pt 1):737-45. PubMed ID: 11329231
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
    Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI.
    N Engl J Med; 1998 Mar 26; 338(13):867-72. PubMed ID: 9516221
    [Abstract] [Full Text] [Related]

  • 4. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
    Kumar S, Boulton AJ, Beck-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S, Stewart-Long P.
    Diabetologia; 1996 Jun 26; 39(6):701-9. PubMed ID: 8781766
    [Abstract] [Full Text] [Related]

  • 5. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.
    Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW.
    J Clin Endocrinol Metab; 1998 Sep 26; 83(9):3169-76. PubMed ID: 9745421
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
    Sironi AM, Vichi S, Gastaldelli A, Pecori N, Anichini R, Foot E, Seghieri G, Ferrannini E.
    Clin Pharmacol Ther; 1997 Aug 26; 62(2):194-202. PubMed ID: 9284856
    [Abstract] [Full Text] [Related]

  • 9. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
    Kumar S, Prange A, Schulze J, Lettis S, Barnett AH.
    Diabet Med; 1998 Sep 26; 15(9):772-9. PubMed ID: 9737807
    [Abstract] [Full Text] [Related]

  • 10. Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group.
    Buse JB, Gumbiner B, Mathias NP, Nelson DM, Faja BW, Whitcomb RW.
    Diabetes Care; 1998 Sep 26; 21(9):1455-61. PubMed ID: 9727891
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
    Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T.
    Diabet Med; 1996 Apr 26; 13(4):365-70. PubMed ID: 9162613
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.
    Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW.
    Diabetes Care; 1998 Sep 26; 21(9):1462-9. PubMed ID: 9727892
    [Abstract] [Full Text] [Related]

  • 16. Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics.
    Iwatani M, Wasada T, Katsumori K, Watanabe-Takahashi C, Kamatani N, Iwamoto Y.
    Diabetologia; 2000 Jun 26; 43(6):814-5. PubMed ID: 10907128
    [No Abstract] [Full Text] [Related]

  • 17. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
    Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.
    Diabetes Care; 2002 Mar 26; 25(3):542-9. PubMed ID: 11874944
    [Abstract] [Full Text] [Related]

  • 18. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
    Yu JG, Kruszynska YT, Mulford MI, Olefsky JM.
    Diabetes; 1999 Dec 26; 48(12):2414-21. PubMed ID: 10580431
    [Abstract] [Full Text] [Related]

  • 19. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
    Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI.
    Ann Intern Med; 1998 Feb 01; 128(3):176-85. PubMed ID: 9454525
    [Abstract] [Full Text] [Related]

  • 20. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.
    Raskin P, Jovanovic L, Berger S, Schwartz S, Woo V, Ratner R.
    Diabetes Care; 2000 Jul 01; 23(7):979-83. PubMed ID: 10895850
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.